473 related articles for article (PubMed ID: 15123578)
1. Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy.
Matsui Y; Jia N; Okamoto H; Kon S; Onozuka H; Akino M; Liu L; Morimoto J; Rittling SR; Denhardt D; Kitabatake A; Uede T
Hypertension; 2004 Jun; 43(6):1195-201. PubMed ID: 15123578
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling.
Weisberg AD; Albornoz F; Griffin JP; Crandall DL; Elokdah H; Fogo AB; Vaughan DE; Brown NJ
Arterioscler Thromb Vasc Biol; 2005 Feb; 25(2):365-71. PubMed ID: 15576638
[TBL] [Abstract][Full Text] [Related]
3. Apoptosis signal-regulating kinase 1 plays a pivotal role in angiotensin II-induced cardiac hypertrophy and remodeling.
Izumiya Y; Kim S; Izumi Y; Yoshida K; Yoshiyama M; Matsuzawa A; Ichijo H; Iwao H
Circ Res; 2003 Oct; 93(9):874-83. PubMed ID: 14551246
[TBL] [Abstract][Full Text] [Related]
4. Osteopontin modulates angiotensin II-induced fibrosis in the intact murine heart.
Collins AR; Schnee J; Wang W; Kim S; Fishbein MC; Bruemmer D; Law RE; Nicholas S; Ross RS; Hsueh WA
J Am Coll Cardiol; 2004 May; 43(9):1698-705. PubMed ID: 15120833
[TBL] [Abstract][Full Text] [Related]
5. Cardioprotective effects of granulocyte colony-stimulating factor in angiotensin II-induced cardiac remodelling.
Jia N; Dong P; Huang Q; Jin W; Zhang J; Dai Q; Liu S
Clin Exp Pharmacol Physiol; 2009 Mar; 36(3):262-6. PubMed ID: 18785976
[TBL] [Abstract][Full Text] [Related]
6. Early onset of chondroitin sulfate and osteopontin expression in angiotensin II-dependent left ventricular hypertrophy.
Rothermund L; Kreutz R; Kossmehl P; Fredersdorf S; Shakibaei M; Schulze-Tanzil G; Paul M; Grimm D
Am J Hypertens; 2002 Jul; 15(7 Pt 1):644-52. PubMed ID: 12118914
[TBL] [Abstract][Full Text] [Related]
7. Baicalein attenuates angiotensin II-induced cardiac remodeling via inhibition of AKT/mTOR, ERK1/2, NF-κB, and calcineurin signaling pathways in mice.
Wang AW; Song L; Miao J; Wang HX; Tian C; Jiang X; Han QY; Yu L; Liu Y; Du J; Xia YL; Li HH
Am J Hypertens; 2015 Apr; 28(4):518-26. PubMed ID: 25362112
[TBL] [Abstract][Full Text] [Related]
8. Differential role of TIMP2 and TIMP3 in cardiac hypertrophy, fibrosis, and diastolic dysfunction.
Fan D; Takawale A; Basu R; Patel V; Lee J; Kandalam V; Wang X; Oudit GY; Kassiri Z
Cardiovasc Res; 2014 Jul; 103(2):268-80. PubMed ID: 24692173
[TBL] [Abstract][Full Text] [Related]
9. Osteopontin modulates myocardial hypertrophy in response to chronic pressure overload in mice.
Xie Z; Singh M; Singh K
Hypertension; 2004 Dec; 44(6):826-31. PubMed ID: 15534078
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction.
Zhong J; Basu R; Guo D; Chow FL; Byrns S; Schuster M; Loibner H; Wang XH; Penninger JM; Kassiri Z; Oudit GY
Circulation; 2010 Aug; 122(7):717-28, 18 p following 728. PubMed ID: 20679547
[TBL] [Abstract][Full Text] [Related]
11. Profibrotic effects of angiotensin II in the heart: a matter of mediators.
Díez J
Hypertension; 2004 Jun; 43(6):1164-5. PubMed ID: 15117918
[No Abstract] [Full Text] [Related]
12. Apocynin attenuates oxidative stress and cardiac fibrosis in angiotensin II-induced cardiac diastolic dysfunction in mice.
Li YQ; Li XB; Guo SJ; Chu SL; Gao PJ; Zhu DL; Niu WQ; Jia N
Acta Pharmacol Sin; 2013 Mar; 34(3):352-9. PubMed ID: 23334241
[TBL] [Abstract][Full Text] [Related]
13. Differences in cell-type-specific responses to angiotensin II explain cardiac remodeling differences in C57BL/6 mouse substrains.
Cardin S; Scott-Boyer MP; Praktiknjo S; Jeidane S; Picard S; Reudelhuber TL; Deschepper CF
Hypertension; 2014 Nov; 64(5):1040-6. PubMed ID: 25069667
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart.
Mercure C; Yogi A; Callera GE; Aranha AB; Bader M; Ferreira AJ; Santos RA; Walther T; Touyz RM; Reudelhuber TL
Circ Res; 2008 Nov; 103(11):1319-26. PubMed ID: 18845809
[TBL] [Abstract][Full Text] [Related]
15. Guanylyl cyclase-A inhibits angiotensin II type 1A receptor-mediated cardiac remodeling, an endogenous protective mechanism in the heart.
Li Y; Kishimoto I; Saito Y; Harada M; Kuwahara K; Izumi T; Takahashi N; Kawakami R; Tanimoto K; Nakagawa Y; Nakanishi M; Adachi Y; Garbers DL; Fukamizu A; Nakao K
Circulation; 2002 Sep; 106(13):1722-8. PubMed ID: 12270869
[TBL] [Abstract][Full Text] [Related]
16. Adiponectin mediates cardioprotection in oxidative stress-induced cardiac myocyte remodeling.
Essick EE; Ouchi N; Wilson RM; Ohashi K; Ghobrial J; Shibata R; Pimentel DR; Sam F
Am J Physiol Heart Circ Physiol; 2011 Sep; 301(3):H984-93. PubMed ID: 21666115
[TBL] [Abstract][Full Text] [Related]
17. The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice.
Yamazaki T; Yamashita N; Izumi Y; Nakamura Y; Shiota M; Hanatani A; Shimada K; Muro T; Iwao H; Yoshiyama M
Hypertens Res; 2012 Jan; 35(1):34-40. PubMed ID: 21866107
[TBL] [Abstract][Full Text] [Related]
18. Osteopontin deficiency protects against aldosterone-induced inflammation, oxidative stress, and interstitial fibrosis in the kidney.
Irita J; Okura T; Jotoku M; Nagao T; Enomoto D; Kurata M; Desilva VR; Miyoshi K; Matsui Y; Uede T; Denhardt DT; Rittiling SR; Higaki J
Am J Physiol Renal Physiol; 2011 Oct; 301(4):F833-44. PubMed ID: 21734100
[TBL] [Abstract][Full Text] [Related]
19. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling.
Stas S; Whaley-Connell A; Habibi J; Appesh L; Hayden MR; Karuparthi PR; Qazi M; Morris EM; Cooper SA; Link CD; Stump C; Hay M; Ferrario C; Sowers JR
Endocrinology; 2007 Aug; 148(8):3773-80. PubMed ID: 17494996
[TBL] [Abstract][Full Text] [Related]
20. Eplerenone prevents adverse cardiac remodelling induced by pressure overload in atrial natriuretic peptide-null mice.
Franco V; Chen YF; Feng JA; Li P; Wang D; Hasan E; Oparil S; Perry GJ
Clin Exp Pharmacol Physiol; 2006 Sep; 33(9):773-9. PubMed ID: 16922805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
